Running summarizing tools on a new article

Abstract: Background The gut microbiome is a key regulator of immune response to immune checkpoint inhibitors (ICIs), influencing both anti-tumor efficacy and immune-related adverse events (irAEs). Microbiome-derived metabolites, particularly short-chain fatty acids such as butyrate, have been shown to modulate T-cell differentiation, epithelial barrier integrity, and inflammatory signaling. 1–3 More recently, the randomized phase II TACITO trial demonstrated that therapeutic microbiome modulation through fecal microbiota transplantation can improve clinical outcomes in patients receiving ICI-based therapy, providing proof-of-concept that the gut microbiome represents a clinically actionable target in cancer immunotherapy.4 Despite these advances, prospective interventions aimed at optimizing microbiome composition through well tolerated and scalable microbiome-based approaches remain limited. This study investigates whether targeted microbiome modulation with a butyrate-based microbiome intervention can improve the therapeutic index of ICIs.Methods This is a randomized, open-label, exploratory clinical trial enrolling 40 patients with advanced ICI-sensitive solid tumors, including melanoma, cutaneous squamous cell carcinoma (cSCC), Merkel cell carcinoma and non small cell lung cancer (NSCLC). Patients are randomized 1:1 to receive standard ICI therapy with or without FEEDColon, an oral formulation containing calcium butyrate, Bifidobacterium bifidum, Bifidobacterium lactis and fruit-oligosaccharides. Key eligibility criteria include age > 18 years, ECOG performance status 0–1 and adequate organ function. Patients with prior ICI exposure or active autoimmune disease requiring systemic therapy are excluded. The investigational intervention is administered daily starting at ICI initiation and continued for up to 24 months or until treatment discontinuation. Clinical outcomes and toxicity (graded according to CTCAE v5.0) are prospectively collected. Radiologic response is assessed per RECIST 1.1 criteria. Serial stool samples are collected at baseline and during treatment for microbiome profiling, including taxonomic and metabolic analyses. The study is designed to generate preliminary clinical, microbiome, and biomarker data associated with gastrointestinal irAEs and treatment outcomes.References Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359:97–103.Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359:91–97.Spencer CN, McQuade JL, Gopalakrishnan V, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy outcomes. Science 2021;374:1632–1640.Porcari S, Ciccarese C, Heidrich V, et al. Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial. Nature Medicine 2026;32:1316–1324. doi:10.1038/s41591-025-04189-2.